Abstract：
Breast cancer (BC) remains a significant health burden worldwide, necessitating the development of innovative therapeutic strategies. The B-cell lymphoma 2 (Bcl-2) family proteins, Bcl-2 and Bax, play a crucial role in regulating apoptosis and thus are promising targets for BC therapy. We focus on the recent advancements in novel formulations that specifically target Bcl-2/Bax pathway to combat BC. It provides an overview on biological functions of Bcl-2/Bax in apoptosis regulation, emphasizing their significance in pathogenesis and progression of the disease while covering the numerous therapeutic approaches aimed at modulating the Bcl-2/Bax pathway, including small-molecule inhibitors, peptides, gene-based therapies and other repurposed drugs harboured onto cutting-edge technologies and nanocarrier systems employed to enhance the targeted delivery of Bcl-2/Bax inhibitors tumor cells. These advanced formulations aim to improve therapeutic efficacy, minimize off-target effects, and overcome drug resistance, offering promising prospects in its treatment. In conclusion, it illuminates the diverse and evolving landscape of novel formulations as an essential armament in targeting these proteins while bridging and unravelling the obscurity of Bcl-2/Bax pathway-targeted drug delivery systems which are presently in their nascent stages of exploration for BC therapy which can benefit researchers, clinicians, and pharmaceutical scientists.
摘要：
乳腺癌（BC）仍然是全球重大的健康负担，需要开发创新的治疗策略。B细胞淋巴瘤2(Bcl-2)家族蛋白,Bcl-2和Bax,在调节细胞凋亡中起着至关重要的作用，因此是BC治疗的有希望的靶标。我们专注于特异性靶向Bcl-2/Bax途径以对抗BC的新型制剂的最新进展。综述了Bcl-2/Bax在细胞凋亡调控中的生物学功能,强调它们在疾病的发病机理和进展中的意义，同时涵盖了旨在调节Bcl-2/Bax通路的众多治疗方法，包括小分子抑制剂，肽，基于基因的疗法和其他用途的药物包含在尖端技术和纳米载体系统上，用于增强Bcl-2/Bax抑制剂肿瘤细胞的靶向递送。这些先进的配方旨在提高治疗效果，最小化脱靶效应，克服耐药性，为其治疗提供了有希望的前景。总之,它阐明了新型制剂的多样化和不断发展的景观，作为靶向这些蛋白质的重要武器，同时桥接和解开了Bcl-2/Bax途径靶向药物递送系统的模糊性，这些系统目前正处于BC疗法探索的初期阶段，可以使研究人员受益，临床医生,和制药科学家。
